128 related articles for article (PubMed ID: 20395521)
1. Fixation time does not affect the expression of estrogen receptor.
Ibarra JA; Rogers LW; Kyshtoobayeva A; Bloom K
Am J Clin Pathol; 2010 May; 133(5):747-55. PubMed ID: 20395521
[TBL] [Abstract][Full Text] [Related]
2. Fixation time does not affect expression of HER2/neu: a pilot study.
Ibarra JA; Rogers LW
Am J Clin Pathol; 2010 Oct; 134(4):594-6. PubMed ID: 20855640
[TBL] [Abstract][Full Text] [Related]
3. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones.
Qiu J; Kulkarni S; Chandrasekhar R; Rees M; Hyde K; Wilding G; Tan D; Khoury T
Am J Clin Pathol; 2010 Nov; 134(5):813-9. PubMed ID: 20959666
[TBL] [Abstract][Full Text] [Related]
4. Protein and gene expression of estrogen receptor alpha and nuclear morphology of two breast cancer cell lines after different fixation methods.
Nykänen M; Kuopio T
Exp Mol Pathol; 2010 Apr; 88(2):265-71. PubMed ID: 20025868
[TBL] [Abstract][Full Text] [Related]
5. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Goldstein NS; Ferkowicz M; Odish E; Mani A; Hastah F
Am J Clin Pathol; 2003 Jul; 120(1):86-92. PubMed ID: 12866377
[TBL] [Abstract][Full Text] [Related]
6. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Yildiz-Aktas IZ; Dabbs DJ; Cooper KL; Chivukula M; McManus K; Bhargava R
Am J Clin Pathol; 2012 May; 137(5):691-8. PubMed ID: 22523206
[TBL] [Abstract][Full Text] [Related]
7. Fixation time does not affect expression of HER2/neu.
Goldsmith JD; Allred DC; Beasley MB; Eisen R; Fulton RS; Gown AM; Hammond ME
Am J Clin Pathol; 2011 Mar; 135(3):484; author reply 485. PubMed ID: 21350107
[No Abstract] [Full Text] [Related]
8. Fixation time does not affect the expression of estrogen receptor.
Dabbs DJ; Bhargava R
Am J Clin Pathol; 2011 Jan; 135(1):171-2; author reply 172. PubMed ID: 21173141
[No Abstract] [Full Text] [Related]
9. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma.
Apple S; Pucci R; Lowe AC; Shintaku I; Shapourifar-Tehrani S; Moatamed N
Am J Clin Pathol; 2011 Apr; 135(4):592-8. PubMed ID: 21411782
[TBL] [Abstract][Full Text] [Related]
10. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma.
Gong Y; Symmans WF; Krishnamurthy S; Patel S; Sneige N
Cancer; 2004 Feb; 102(1):34-40. PubMed ID: 14968416
[TBL] [Abstract][Full Text] [Related]
11. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results.
Brock JE; Hornick JL; Richardson AL; Dillon DA; Lester SC
Am J Clin Pathol; 2009 Sep; 132(3):396-401. PubMed ID: 19687316
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of estrogen receptors in mammary carcinomas. Is immunocytochemical determination after formalin fixation sufficient?].
Haugen OA; Aasmundstad T; Johannesen E; Ytterhus B; Nervik I
Tidsskr Nor Laegeforen; 1993 Mar; 113(8):944-6. PubMed ID: 8470071
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
14. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.
Rocha R; Nunes C; Rocha G; Oliveira F; Sanches F; Gobbi H
Pathol Res Pract; 2008; 204(9):655-62. PubMed ID: 18565685
[TBL] [Abstract][Full Text] [Related]
15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
16. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation.
Penault-Llorca F; Adelaïde J; Houvenaeghel G; Hassoun J; Birnbaum D; Jacquemier J
J Pathol; 1994 May; 173(1):65-75. PubMed ID: 7931839
[TBL] [Abstract][Full Text] [Related]
17. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections.
Huang Z; Zhu W; Szekeres G; Xia H
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):91-5. PubMed ID: 15722800
[TBL] [Abstract][Full Text] [Related]
18. Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics.
Kalkman S; Barentsz MW; Witkamp AJ; van der Wall E; Verkooijen HM; van Diest PJ
Am J Surg Pathol; 2014 Aug; 38(8):1071-8. PubMed ID: 24705310
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives.
Hudock JA; Hanau CA; Christen R; Bibbo M
Diagn Cytopathol; 1996 Jul; 15(1):78-83. PubMed ID: 8807259
[TBL] [Abstract][Full Text] [Related]
20. Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.
Maleki S; Dorokhova O; Sunkara J; Schlesinger K; Suhrland M; Oktay MH
Diagn Cytopathol; 2013 Oct; 41(10):864-70. PubMed ID: 23447357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
